Brain Tumor Imaging

Kevin M. Brindle, José L. Izquierdo-García, David Y. Lewis, Richard J. Mair, and Alan J. Wright

ABSTRACT

Modern imaging techniques, particularly functional imaging techniques that interrogate some specific aspect of underlying tumor biology, have enormous potential in neuro-oncology for disease detection, grading, and tumor delineation to guide biopsy and resection; monitoring treatment response; and targeting radiotherapy. This brief review considers the role of magnetic resonance imaging and spectroscopy, and positron emission tomography in these areas and discusses the factors that limit translation of new techniques to the clinic, in particular, the cost and difficulties associated with validation in multicenter clinical trials.

J Clin Oncol 35. © 2017 by American Society of Clinical Oncology

MAGNETIC RESONANCE IMAGING AND SPECTROSCOPY

Basic Principles

Magnetic resonance (MR) images of tissue water protons can be used to generate relatively high-resolution maps of tissue anatomy (mm resolution at the relatively low magnetic field strengths used routinely in the clinic [1.5 and 3T]). The strength of MR imaging and the reason that it gives much better soft tissue contrast than computed tomography is that the intensities of these proton signals are dependent not only on water distribution but also on the nuclear MR relaxation properties of the water proton spins, which are characterized by the relaxation times $T_1$ and $T_2$. These are influenced by the molecular composition of the tissue; for example, $T_2$ is shortened by the presence of paramagnetic iron in deoxygenated hemoglobin found in hypoxic regions, and $T_1$ can be shortened by gadolinium-containing contrast agents. The way that the image is acquired can be used to emphasize the effect of $T_1$ or $T_2$ and therefore make signal intensity more sensitive to specific aspects of tissue composition. The signal is also sensitive to diffusion, and again, by changing acquisition parameters, the image can be made more sensitive to the effects of water diffusion. MR images can be acquired as a series of two-dimensional slices or as a genuine three-dimensional acquisition. Slice thickness is usually much greater than the in-plane resolution; therefore, multislice images have low resolution in one dimension. Three-dimensional images can be acquired with isotropic image resolution but are time consuming to acquire and usually have a resolution $>1$ mm. These resolution limitations are usually not critical for brain tumors because they are sufficient for diagnostic purposes, planning biopsies, and targeting radiotherapy. However, a limitation is that infiltrative tumor growth cannot be visualized directly with standard anatomic MR imaging. Image analysis algorithms can be used to improve the diagnostic or prognostic value of these images. This includes radiomics (reviewed in Gillies et al4), in which images are analyzed quantitatively on a voxel-by-voxel basis.

As well as detecting water, the technique can also be used to detect small molecule metabolites. These are usually detected via their proton resonances, because the proton is, with the exception of tritium, the most sensitive to MR detection; however, because these metabolites are present at $10^4$ to $10^5$ lower concentrations than tissue water, they can only be imaged at relatively low spatial and temporal resolutions. The brain is well suited to investigation by MR techniques because it is relatively superficial, there is minimal respiratory- or cardiac-dependent motion, and the tissue is, with the exception of positron emission tomography (PET), less accessible to other noninvasive functional imaging modalities (optical, photoacoustic).

A standard protocol, which can be acquired in approximately 20 minutes, has been proposed for imaging brain tumors, consisting of $T_1$- and $T_2$-weighted sequences, some after contrast agent administration (contrast-enhanced MR imaging [CE-MRI]) and a fluid-attenuated inversion

https://doi.org/10.1200/JCO.2017.0732-183X/17/3599-1/$20.00

© 2017 by American Society of Clinical Oncology
recovery sequence that suppresses signal from cerebral spinal fluid. Images acquired using this protocol have been used for assessing treatment response, using the Response Assessment in Neuro-Oncology Criteria for glioma, which are based on changes in tumor size, and whether there is blood-brain barrier (BBB) breakdown on CE-MRI. This protocol can also be used for diagnosis and for assessing progression in follow-up scans after surgery or radiotherapy. Serial monitoring of patients with glioma after therapy can be used to determine recurrence or progression through increased contrast enhancement. However, in the first 3 months after treatment, contrast agent enhancement can increase due to damage to normal brain tissue, a phenomenon known as pseudoprogression. This standard MR protocol is poor at distinguishing between pseudoprogression and real progression; therefore, the patient must often wait an additional 3 months for a prognostic assessment.

**Functional Imaging**

Anatomic images can be complemented by additional functional images that measure a specific biologic property. Diffusion-weighted MRI (DW-MRI) can be used to assess treatment response, the loss of tumor cellularity post-treatment leading to an increase in the apparent diffusion coefficient of tissue water. Dynamic contrast-enhanced MRI, with two or three b values between 0 and 1,000 s/mm², has been proposed for routine imaging of patients with brain tumors and can be used to monitor response to radiotherapy and chemotherapy. The technique can also be used to distinguish between tumors and abscesses. Dynamic contrast-enhanced MRI can be used to measure the flow of contrast agent across a damaged BBB, whereas dynamic susceptibility MRI can be used to indicate angiogenic regions of a tumor, regardless of BBB integrity. Perfusion MRI techniques are particularly useful for grading glioma. Although it is unlikely that functional imaging modalities could ever be as accurate or as cost effective as biopsy for the purpose of diagnosis or grading, particularly with the growing importance of predictive genomic and epigenomic biomarkers, they can nevertheless be used to target biopsies. For example, using CE-MRI, which in glioma reveals BBB breakdown in areas that likely contain high-grade tumor. Functional imaging modalities would appear to have greater potential in distinguishing true progression from pseudoprogression. For example, dynamic susceptibility MRI and MR spectroscopic imaging (MRSI) have shown promise in discriminating pseudoprogression from recurrence. Amide proton transfer MRI, in which mobile peptides and proteins are detected using chemical exchange saturation transfer, has shown some promise in monitoring progression. In an animal model, the technique was shown to distinguish tumor recurrence from radiation necrosis, and Park et al showed that amide proton transfer may be better than MRSI in this regard. Identifying early recurrence may enable reirradiation or the initiation of alternative treatments.

MR spectroscopy (MRS) and spectroscopic imaging of brain tumor metabolites has been reviewed recently. Grading of cerebral neoplasms has been attempted by analyzing the profile of metabolites detected in 1H MR spectra of tumors in vivo. However, although it shows improved sensitivity and specificity compared with anatomic imaging, this technique has so far failed to provide the diagnostic certainty required for widespread clinical acceptance. Discovery of the isocitrate dehydrogenase (IDH) 1 mutation in 70% to 90% of low-grade gliomas and secondary glioblastomas has led to a new diagnostic paradigm where mutant IDH1 tumors are associated with a more favorable prognosis. Human gliomas expressing mutant IDH 1 and 2 have been identified by 1H MRS detection of the oncometabolite and product of mutant IDH, 2-hydroxyglutarate. Loss of 2-hydroxyglutarate has been used to assess treatment response.

In summary, functional imaging methods have been demonstrated to provide additional information for diagnosis, delineating tumor margins, staging, monitoring treatment response, detecting recurrence, and monitoring disease progression. Although the utility of individual functional imaging methods for specific applications have been compared, when combined in multiparametric MRI protocols they can collectively give better sensitivity and specificity. However, multiparametric methods require extra scan time and have inherent systematic errors, which are difficult to correct for, limiting comparison of absolute parameter values between different instruments and protocols.

**Guiding Surgery and Radiotherapy**

Maximal surgical resection is prognostic for low- and high-grade glioma. However, complete resection must be balanced against the risk of neurologic morbidity. Preoperative resection planning and intraoperative surgical resection margins can be informed by determining eloquent brain regions, such as white matter tracts, using diffusion tensor imaging (DTI). Improvements in the algorithms that calculate the probable position of these white matter tracts from DTI data have allowed preservation of language pathways and also assessment of pathway damage postsurgery. Eloquent brain regions can also be determined using functional MRI (fMRI). The patient is imaged while performing certain tasks to map regions of the cortex for speech and motor function. Petrella et al showed that fMRI allowed a more aggressive resection strategy and Berntsen et al showed that a combination of fMRI and DTI led to changes in resection margins and even a complete change in therapeutic strategy. Despite these advances, variable sensitivity and specificity have been reported and, as such, the gold standard—intraoperative mapping with electrodes during awake brain surgery—remains the mainstay in regions adjacent to eloquent cortex. Imaging can also be used to identify regions within tumors that exhibit poor prognostic features and therefore could be used to target radiation, increasing dose to more aggressive areas. This approach will be facilitated by the recent introduction of the MR-linac, in which a linear accelerator is incorporated into a split magnet to allow real-time MRI guidance and monitoring of radiotherapy.

**Detecting Treatment Response**

When MR is being used in a clinical trial of a new drug to assess treatment response, it would be best to choose a functional imaging technique that is tailored to detect the expected readout. For example, perfusion imaging has the potential to show whether an antiangiogenic drug has hit its target, the change in contrast enhancement providing a faster readout of treatment response than monitoring changes in tumor size using Revised Assessment in Neuro-Oncology criteria. The implementation of a multiparametric MRI protocol for post-therapy monitoring of patients with brain tumors should therefore be patient-group and therapy.
specific. Development of such protocols will require large, multicenter trials to find the best combination of MRI methods for accurately detecting treatment response and to standardize image acquisition and analysis across multiple sites and vendor instruments.

**Increasing Sensitivity**

A fundamental limitation, particularly of MRS, has been a lack of sensitivity, which can result in long image acquisition times. The introduction of high-field (7 Tesla) instruments into the clinic, in combination with parallel imaging and MR fingerprinting, will increase sensitivity and should reduce scan times, although it remains to be seen whether there will be widespread introduction of these high-field machines into the clinic. The sensitivity of spectroscopic measurements of tissue metabolism can also be increased by the use of hyperpolarized 13C-labeled cell metabolites. Nuclear spin hyperpolarization of 13C-labeled substrates increases their sensitivity to detection in the 13C MRS(I) experiment by 104-fold to 107-fold, allowing real-time imaging of metabolic fluxes in vivo. The 13C nuclear spins in a labeled substrate are first hyperpolarized in a separate low temperature process (approximately 1.2 K) at high magnetic fields; the frozen sample is then warmed rapidly to room temperature and injected intravenously into the patient. The hyperpolarized 13C signal can be used to image the location of the labeled substrate in the body and its metabolic transformation into other metabolites, although the transient nature of the hyperpolarized 13C signal (the half-life in the body is approximately 30 seconds) means that only fast metabolic processes can be studied over relatively limited spatial regions.

Nevertheless, the technique has already translated to the clinic with an initial study in prostate cancer, and studies are under way on other cancers, including glioma. The majority of studies have used pyruvate because it is rapidly taken up by cells and metabolized and is a key metabolite that sits at the junction between glycolysis and the tricarboxylic acid cycle (Fig 1). Early studies focused on monitoring treatment response and disease progression in animal models. Initial studies in glioma xenografts reported increased [1-13C]lactate production from [1-13C]pyruvate in brain tumors versus normal brain as a result of upregulation of aerobic glycolysis. Lower [1-13C]lactate levels were found after treatment of orthotopic glioblastoma xenografts with the mammalian target of rapamycin inhibitor everolimus, and the efficacy of temozolomide alone or in combination with a second-generation dual PI3K/mammalian target of rapamycin inhibitor, voxtalisib, has been demonstrated. The hyperpolarized [1-13C]lactate-to-[1-13C]pyruvate ratio has been proposed as a biomarker of response to radiotherapy (Fig 2). The production of [1-13C]2-hydroxyglutarate, after injection of hyperpolarized [1-13C]α-ketoglutarate has been used to image IDH1 status in orthotopic xenografts, and the conversion of hyperpolarized [1-13C] α-ketoglutarate to glutamate was shown to be reduced in mutant IDH1 tumors.

**Basic Principles**

A short half-life positron-emitting isotope (eg, 18F, half-life 110 minutes; 11C, half-life 20 minutes) generated in a cyclotron is incorporated into a tracer and then injected intravenously into the patient. The emitted positron (antielectron) migrates a short distance (typically less than 1 mm) before colliding with an electron. The subsequent annihilation event results in the emission of two 511 keV γ-rays at almost exactly 180° with respect to each other. The gamma rays are used to generate a tomographic image, which is then analyzed to provide functional information about the tissue under study.

![Schematic illustration of metabolic pathways observable using hyperpolarized 13C-labeled probes](image-url)
other. These are detected by a circular array of scintillation detectors placed around the subject. If two detectors are struck effectively simultaneously, then one can deduce that the positron-emitting isotope must lie on a line between these two detectors. By collecting data from multiple annihilation events, back-projection reconstruction methods can be used to generate an image of the location of the labeled material in the body. If attenuation of the γ-rays by body tissues is corrected for, the technique can generate quantitative images with picomolar sensitivity. PET detector arrays are often used in conjunction with computer tomography, which provides an anatomic image for positional reference. More recently, with the development of detectors that are insensitive to the effects of magnetic fields, PET/MR machines have been introduced into the clinic. These combine the contrast mechanisms available with MRI with the molecular information provided by PET and promise to increase the specificity of the imaging exam. For example, a decrease in tumor uptake of the glucose analog $[18F]$-fluorodeoxyglucose (FDG) may be a reflection of cell death or a metabolic change in the tumor; by combining the FDG-PET exam with DW-MRI measurements, it may be possible to distinguish between these two possibilities.

PET can be used for whole-body mapping of biologic processes and has been used in neuro-oncology when anatomic imaging is ambiguous for primary or differential diagnosis, noninvasive grading, prognostication, surveillance after radiotherapy, chemotherapy and surgery and for tumor delineation for targeting biopsy, resection, and irradiation.

The majority of PET studies in cancer have used the glucose analog FDG, exploiting the high glycolytic demand of many tumors. FDG is widely available but has suboptimal sensitivity in the brain because of poor contrast between the tumor and surrounding cortex and poor specificity because of uptake in nonmalignant lesions. This has led to the development of improved PET tracers for the brain, the most promising of which are the radiolabeled amino acids. Although not yet approved for use in glioma by the Food and Drug Administration in the United States, new clinical guidelines in Europe recommend the use of amino acid PET tracers in preference to FDG wherever possible.

**Radiolabeled Amino Acids**

One of the most widely used radiolabeled amino acids is the essential amino acid methionine, labeled with $^{11}$C, which is taken up by the $\lambda$-type amino acid transporters (LAT) 1 (SLC7A5) and 2 (SLC7A8) and incorporated into protein. Methionine showed a better correlation with cell proliferation than FDG in gliomas. Amino acid PET in gliomas can be used to distinguish pseudoprogressors from genuine treatment failure. However, the short half-life of $^{11}$C requires a local cyclotron; therefore, to increase availability, several fluorinated amino acid analogs have been developed, which can be made at a remote cyclotron and shipped to the imaging facility. The majority of these are not incorporated into proteins and simply measure amino acid uptake. $[18F]$-fluoroethyltyrosine (FET) and $[18F]$-fluorodihydroxyphenylalanine are substrates for LAT1 and LAT2 and are widely used in place of methionine. FET has advantages over methionine and $[18F]$-fluorodihydroxyphenylalanine in that there is less inflammatory and striatal uptake, respectively, and, unlike the other amino acids, FET can distinguish high- and low-grade gliomas on the basis of tracer kinetics. $[4\text{F}]{\text{F}}\text{F}2\text{S}4\text{R}$-fluoroglutamine, which was developed to image glutaminolysis, showed high levels of uptake in glioblastoma, and it was suggested that it may be useful for patient management. A glutamate analog, (4S)-4-(3-[[18F]fluoropropyl]-1-glutamate, with affinity for the cystine/glutamate (SLC7A11) transporter, gave high levels of contrast in human patients with primary and secondary brain tumors. (4S)-4-([18F]fluoropropyl)-1-glutamate potentially could be used to assess response to oxidative stress and may therefore have a role in therapy selection. Trans-1-amino-3-[18F]-fluorocyclobutane-carboxylic acid is a leucine analog that shows high uptake in glioma and was shown to be better able to delineate tumor spread than CE-MRI.

**Other Metabolic Tracers**

The nucleoside analog, 3′-deoxy-3′-[18F]-fluorothymidine, which was developed to image tumor cell proliferation, has been used for imaging early treatment response and predicting clinical outcome in brain tumors. However, there are instances where 3′-deoxy-3′-[18F]-fluorothymidine does not correlate with proliferation rate. Human glioblastomas have been shown to oxidize acetate, which was suggested to be an important bioenergetic and biosynthetic substrate. $^{11}$C-acetate can be used to assess the capacity for mitochondrial oxidation and tumor fatty acid synthesis and has been suggested to be a potentially useful tracer for detecting and grading glioblastoma. $[18F]$fluoromisonidazole is reduced and retained by viable hypoxic cancer cells and is used for defining hypoxic volumes and for...
noninvasive grading of glioma. An attractive application is escalating radiotherapy doses to [18F]fluoromisonidazole-positive tumor regions, which are hypoxic and therefore likely to be radioresistant. Studies are under way to determine whether there is any clinical benefit from this approach.

In conclusion, imaging techniques, particularly more sophisticated functional or molecular imaging techniques, are perceived as being expensive. However, modern targeted therapies are also expensive; for example, treatment of patients with glioma with a course of bevacizumab cost $80,000 in 2015. If imaging can distinguish responders from nonresponders early during the course of treatment, there are potential financial benefits for the health care system, as well as welfare benefits for the patient. Although imaging costs can be brought down by centralization, for example, the production of FDG at a limited number of centers, the distributed nature of the imaging facilities themselves means that it is difficult to reduce costs further. Nevertheless, if the imaging technique addresses an unmet clinical need, then health care systems are prepared to meet this; witness the widespread implementation of FDG-PET in oncology.

The demonstration that response can also be detected through the release of circulating tumor DNA, something that is relatively easy to collect throughout the course of treatment, requires a consideration of how imaging can be used alongside measurement of new and emerging circulating biomarkers in the future. Ultimately, imaging will only be used widely and routinely if it addresses an unmet clinical need that cannot be satisfied by competing technologies. In this respect, the capability of imaging is unique when used to guide surgery or have multiple local on-site imaging facilities brings the additional problems of standardization and validation when introducing a new imaging technique into the clinic.

Imaging, and in particular, molecular imaging, is likely to play an increasingly important role in guiding treatment as more targeted therapies transition to the clinic. However, imaging of early treatment response is only one way in which we can select the treatment of individual patients. Pretreatment genomic analysis of tumor biopsies or of circulating tumor DNA is also likely to play an increasingly important role in treatment selection. Until relatively recently, imaging of tumor size was the only way to obtain an indication of treatment response. The demonstration that response can also be detected through the release of circulating tumor DNA, something that is relatively easy to collect throughout the course of treatment, requires a consideration of how imaging can be used alongside measurement of new and emerging circulating biomarkers in the future. Ultimately, imaging will only be used widely and routinely if it addresses an unmet clinical need that cannot be satisfied by competing technologies. In this respect, the capability of imaging is unique when used to guide surgery or

![Image of Positron emission tomography images and cellular uptake mechanisms for nine clinical radiotracers for brain tumor imaging.](image-url)
biopsy, or spatially targeted treatments, such as intensity-modulated radiotherapy.

**REFERENCES**

4. Gillies RJ, Kinahan PE, Hricak H: Radiomics: Images are more than pictures, they are data. Radiology 278:563-577, 2016
Brain Tumor Imaging


Affiliations
Kevin M. Brindle, Richard J. Mair, and Alan J. Wright, Cancer Research UK Cambridge Institute, Cambridge; David Y. Lewis, Cancer Research UK Beatson Institute, Glasgow, United Kingdom; José L. Izquierdo-García, Fundación Centro Nacional de Investigaciones Cardiovasculares Carlos III and Centro de Investigación Biomédica en Red Enfermedades Respiratorias, Madrid, Spain.
AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Brain Tumor Imaging

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/site/ifc.

Kevin M. Brindle
Research Funding: GE Healthcare (Inst), MedImmune (Inst)
Patents, Royalties, Other Intellectual Property: Patents with GE Healthcare on various aspects of DNP technology

José L. Izquierdo-García
No relationship to disclose

David Y. Lewis
No relationship to disclose

Richard J. Mair
No relationship to disclose

Alan J. Wright
No relationship to disclose